Abstract Neurogranin (Ng) is a dendritic protein associated with synaptic plasticity, proposed to be a novel biomarker to measure synaptic dysfunction and degeneration in Alzheimer's disease. Since electroconvulsive therapy (ECT) has been suggested to facilitate neurogenesis and neural plasticity, we tested whether ECT could modify CSF Ng concentrations measured before and after a course of ECT in 12 patients with major depression. CSF Ng concentrations did not change, but baseline levels were positively correlated with the therapeutic response.
Introduction
Electroconvulsive therapy (ECT) is a highly effective treatment option for severe and treatment-resistant forms of depression. The complex mode of action of ECT has not yet been fully unravelled, but among other mechanism, it is considered to facilitate neurogenesis and neural plasticity (Inta et al. 2013; Rotheneichner et al. 2014; Sartorius et al. 2009 ). Recently, the interplay between antidepressant treatment and amyloid b (Ab) metabolism in humans was investigated by analyzing the antidepressant effects of ECT on Ab peptides in the cerebrospinal fluid (CSF) in patients with major depression. CSF levels of Ab 1-42 , one of the major key players in the pathogenesis of Alzheimer's disease (AD), were elevated after ECT and an increase of Ab was found in all patients with clinical response to ECT, but not in those who did not respond . In contrast to this, Ab 1-40 , tau protein, and its abnormal phosphorylated isoform were not altered by ECT. Similar findings, with no change in CSF tau or another neuronal protein, neurofilament light, was found in another study, indicating that ECT does not induce neuronal damage (Zachrisson et al. 2000) . To complement the evaluation of the effect of ECT on proteins involved in neurodegeneration, we analyzed CSF levels of neurogranin (Ng), a synaptic protein that has been suggested to be a tool to monitor synaptic dysfunction or synaptic degeneration in AD (Mattsson et al. 2016; Kvartsberg et al. 2015) . Ng is a post-synaptic protein (Gerendasy and Sutcliffe 1997) that is expressed in the cortex and hippocampus by excitatory neurons (Represa et al. 1990; Guadano-Ferraz et al. 2005) , has a key role in synaptic plasticity and induction of longterm potentiation (LTP) in the hippocampus (Fedorov et al. 1995; Chen et al. 1997) , and could restore Ab-mediated synaptic plasticity deficits (Kaleka and Gerges 2016) .
Based on these findings, we aimed to test whether the neuronal plasticity, which is known to be enhanced by ECT (Joshi et al. 2016) , is mediated by Ng modulation that could be detected by changes of Ng levels in the CSF in patients who receive ECT due to their major depression.
Methods

Patients
Our prospective study was approved by the ethics committee and all procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The study took place from 2013 to 2015 at the Department of Psychiatry at the Central Institute of Mental Health in Mannheim, Germany. Inclusion criteria were a present depressive episode within the context of a diagnosis of either major depressive disorder or bipolar disorder according to DSM-IV, age above 18 years, and the clinical decision for an ECT treatment. Exclusion criteria were substance-related disorders and a lifetime diagnosis of schizophrenia. The Hamilton Depression Rating Scale (HDRS; 21 items version) and Mini-Mental-State Examination (MMSE) were used to assess the severity of depression and cognitive performance, respectively, before and after ECT. A clinical response to treatment was defined as a reduction of at least 50% of the initial HDRS score during the course of ECT.
ECT treatment
Right unilateral brief pulse ECT was performed with a Thymatron IV device (Somatics, LLC. Lake Bluff, IL, USA). S-ketamine was used as the anaesthetic substance (* 1.0 mg/kg) and succinylcholine was used for muscle relaxation (* 1.0 mg/kg). Seizure threshold in all patients was titrated at the initial session and dosing at subsequent treatments was given at 2.5 times threshold. Seizure monitoring was performed by determining motor convulsive activity with the ''cuff'' method and electroencephalogram monitoring by the ECT device with bilateral frontomastoid leads. The charge was subsequently increased if patients did not respond clinically or if seizures were insufficient during the ECT course according to established recommendations. Two or three ECT sessions per week were performed. All patients started with right unilateral stimulation; in the case of non-response, it was possible to switch to bilateral stimulation as a decision of the ECT supervisor. The patients continued their prior psychotropic medication during the ECT treatment.
Sampling
One day before the first ECT session and between 1 and 7 days after the last ECT session, CSF samples were drawn at around 9:00 am. Lumbar punctures were performed according to standardized procedure. CSF samples were obtained, centrifuged (20009g), aliquoted, and frozen at -80°C within 30 min. The samples were stored at -80°C and were never thawed or refrozen prior to Ng analysis.
CSF laboratory analyses
All samples were measured at the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital. CSF Ng concentration was measured by enzyme-linked immunosorbent assay (ELISA), essentially as described (Kvartsberg et al. 2015) , using the anti-Ng antibody pair Ng2 and Ng22. Baseline and follow-up samples were analyzed on one occasion on the same plates using the same batch of reagents. Intra-assay coefficients of variation were below 10%.
Statistical analyses
Statistics were performed using STATA Ò (StataCorp, TX 77845, USA, version 11) at a significance level B 0.05. Non-parametric tests were used. The impact of ECT on changes in the CSF Ng concentration was calculated with the Wilcoxon matched-pairs signed-ranks test. The difference of changes in the CSF Ng concentration during ECT between responders and non-responders was tested with the Mann-Whitney U test. Correlations were tested with the Spearman's rank correlation. Values below the level of detection (LOD) were substituted with LOD/2 (Ogden 2010).
Results
We included 12 patients into the study, who underwent a completed course of ECT and additionally lumbar puncture before and after. In five samples, neurogranin levels were below the limit of detection of 40 pg/ml (in two patients in both samples and in another patient in the baseline sample). In our sample, three patients (two females, mean age 75.7 ± 6.4) had the clinical diagnosis of an Alzheimer's disease (AD) additional to their current severe depressive episode. Demographic and clinical features are shown in Table 1 .
Differences before and after ECT
CSF Ng concentration at baseline (117.7 pg/ml ± 107.0) and after the complete ECT treatment (122.8 pg/ ml ± 80.4) did not differ from each other (p = 0.15). The mean neurogranin baseline level in the group of those patients suffering from Alzheimer's disease (AD) was higher (179.5 pg/ml ± 77.8) at a trend level significance than the mean level of the patients, who did not suffer from AD (97.1 pg/ml ± 111.0; p = 0.077). The change in neurogranin levels during ECT did not differ in these two groups (p = 0.78).
Correlation with numbers of ECT sessions and time intervals
The changes from baseline to final levels were not associated with the number of single ECT sessions that were performed in each patient (p = 0.74). The CSF Ng changes during ECT was neither affected by amount of days between the both CSF samples (p = 0.70), nor between the amount of days between the last ECT session and the second CSF sample (p = 0.80).
Antidepressant efficacy
The changes of neurogranin levels during ECT were not associated with change of the extent of depressive symptoms during ECT (p = 0.93). The group of responders to the treatment (n = 10) did not differ in terms of changes of Ng concentration during ECT to non-responders (n = 2; p = 0.26). The baseline level of CSF neurogranin was positively correlated with the reduction of depressive psychopathology during ECT ( Fig. 1 ; r s = 0.64; p = 0.024) and the therapeutic response (r s = 0.59; p = 0.045).
Possible moderators
In our sample, CSF neurogranin levels were not associated with age (p = 0.37), sex (p = 0.94), bipolarity (p = 0.93), education (p = 0.51), and MMSE at baseline (p = 0.90).
Discussion
This is the first study to investigate changes of Ng CSF levels in response to ECT treatment in patients suffering from depression. In contrast to the reported changes in the Ab metabolism during ECT ), we could not detect an alteration of the synaptic protein Ng Type of depression: unipolar/bipolar, n/n (%) 9/3 (75.0/25.0) HDRS, sum score Baseline HDRS, mean ± SE (min-max) 29.9 ± 6.6 (21-41)
Final HDRS, mean ± SE (min-max) 9.0 ± 5.2 (3-16)
Mean change (min-max) -20.9 (-6 to -36) (p \ 0.001)
Numbers of ECT sessions, mean ± SE (min-max) 10.6 ± 5.0 (4-19) Switch to bilateral stimulation n (%) 3 (25) Responders/non-responders a , n/n (%) 10/2 (83.4/16.7)
MMSE, sum score Baseline MMSE, mean ± SE (min-max) 26.1 ± 4.3 (17-30)
Final MMSE mean ± SE (min-max) 26.6 ± 3.7 (18-30)
Mean change (min-max) 0.6 (-2 to 4) (p = 0.30) a
Response is defined as a reduction of at least 50% in symptoms, measured by the HDRS Fig. 1 Correlation between CSF Ng levels at baseline and the reduction of the HDRS during ECT (r s = 0.64; p = 0.024) during ECT and no associated with the changes of CSF Ng levels and the number of individual ECT sessions. We found a similar pattern in those patients, who had the diagnosis of AD additional to the major depressive episode, albeit their CSF Ng levels at baseline were higher, as it was expected (Mattsson et al. 2016) . Thus, CSF Ng concentration does not seem to reflect the enhanced neuronal plasticity that has been observed after ECT (Joshi et al. 2016; Sartorius et al. 2016) . As a secondary finding, the baseline level of CSF Ng was positively correlated with the reduction of depressive psychopathology and a better therapeutic response to ECT. Because the role of Ng in mood disorders has not been investigated in-depth yet, our data are the first concerning prediction of antidepressant treatment response based on CSF Ng levels. There is only one previous report, in which data on CSF Ng levels in patients with major depressive disorder were reported. Their cohort consisted only of six patients, but interestingly, all of them had considerable low CSF Ng levels (Sanfilippo et al. 2016) . Although measured by the same group, the research grade assay was modified in-between, which make it impossible to set our data in perspective with the historical data to test whether the Ng concentration in our sample of depressive patients is also lower compared to age-matched healthy controls or to patients with neurodegenerative diseases. One very indirect hint that the CSF Ng concentration in our patients can also be considered as considerable low is that in three out of 12 patients (25%) at baseline the Ng levels were under the limit of detection. At least, no similar pattern was reported in the previous cohorts of healthy controls (Sanfilippo et al. 2016; Portelius et al. 2015) . In addition, Ng has been recognized as a susceptibility gene of major depression and bipolar disorder (and schizophrenia) in Han Chinese (Wen et al. 2016) . Based on these few data, it could be speculated that Ng has indeed a role in the development and treatment of major depression and that it might be worthwhile to evaluate the potential interplay of Ng and depression in more detail.
The major limitation of this study is the small sample size, but the difficulty in recruiting severely depressed patients who agree to undergo lumbar puncture twice for research purposes only in addition to a course of ECT should not be underestimated. It could not be excluded that the insufficient power leads to the negative primary finding. However, it was possible to detect changes in other systems with that small sample size (Kranaster et al. 2017a, b) and at least a strong effect of ECT on Ng appears unlikely. Anyway, our results must be seen as preliminary before a larger dataset could verify our findings. Another shortcoming of the study is that a healthy control group is lacking, and therefore, it could only be speculated about a role for Ng in depression.
In conclusion, mean CSF Ng concentrations did not change during a course of ECT, but the apparently, low baseline Ng levels in the patients with major depression were positively correlated with the amount of therapeutic response, which suggests an involvement of Ng in depression.
